Can an unapproved device ease symptoms? a trial puts it to the test.
NCT ID NCT07719608
First seen Jul 22, 2026 · Last updated Aug 28, 2026 · Updated 9 times
Summary
This trial investigates whether an experimental, unapproved medical device can help relieve symptoms in people with a specific condition. Researchers are enrolling participants to test the device's effects and safety. The goal is to see if this new approach could offer a drug-free way to manage symptoms.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- an unapproved medical device
- What this could lead to
- If it works, this could offer a new option for symptom relief without drugs.
- What could go wrong
- The device is not yet approved, and this early trial may not prove it works or is safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2031
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
22 to 84 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Meets resistant migraine criteria: 1. Documented diagnosis of 1.1 migraine without aura and/or 1.2 migraine with aura and/or 1.3 chronic migraine according to ICHD-3 2. Headache requiring two of the following: * Leads to considerable impairment in personal, educational and/or occupational areas of functioning (MIDAS rating of severe or very severe) * Concomitant continuous or near continuous headache between migraine attacks * Eight or more monthly migraine days 3. Lack of 50% reduction in monthly migraine days and/or intolerable side effects and/or absolute contraindication to three or more (but not all) classes of at least one evidence-based medication. The classes must include Onabotulinumtoxin A and CGRP mabs/antagonists. 4. Not better accounted for by another ICHD-3 diagnosis 4. History of migraine onset before 50 years of age 5. Stable dose of all preventive migraine medication(s) and alternative therapies for at least three months before the start of the eligibility phase Exclusion Criteria: * Presence of another chronic primary or secondary headache disorder, unless the participant can reliably differentiate these headaches attacks from migraine attacks, based on the pain characteristics and associated symptoms * Concurrent use of any invasive or non-invasive neuromodulation. * Previous inadequate response to an implantable neuromodulation device for headache or pain management. * Have an existing active implantable medical device nearby the implant location (e.g. DBS, cochlear implant). * Use of onabotulinum toxin A injections for the treatment of migraine in the past 3 months. Presence of an active implantable medical device (e.g. pacemaker, implantable cardiac defibrillator, neurostimulator, cochlear implant). * Presence of metal or magnet implants in the skull or cranial region (e.g. skull plates, seeds) * Pregnant, nursing or not using contraception.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic migraine headache are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MedStar Health Research Institute
RECRUITINGOlney, Maryland, 20832, United States
-
Queen City Clinical Research, PLLC
RECRUITINGCharlotte, North Carolina, 28211, United States
Contact Email: •••••@•••••
-
Vista Clinical Research
RECRUITINGNewnan, Georgia, 30265, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Talking therapies take on migraine pain
- Exercise, diet, and sleep: a new attack plan against chronic migraine?
- Can a nerve procedure outlast botox for chronic migraine?
- Can a specialized massage outperform classic techniques for migraine sufferers?
- Could blocking an extra nerve double migraine relief?
- Electric zaps to the brain may tame chronic migraine